Veranova has initiated a “significant” expansion of its ADC and highly potent compound development and manufacturing capabilities at Devens, Massachusetts, at a cost of about $30 million. The company said that this will address growing demand for strong US-based capacity for ADCs and other potent small molecules.
French CDMO Seqens has opened its $5 million ‘Seqens Boston R&D Center’ in Devens, Massachusetts, in place of an older one. Covering 14,00 m2, this will be the North American flagship for its ten-strong global network of R&D centres, helping to take projects through all the stages of development to commercialisation.
CDMO and API manufacturer Seqens has announced a “multi-million dollar” investment in its R&D laboratory in Devens, Massachusetts, which is due to be completed in October. The firm said that this will ensure that the new facility can operate at the highest standards of safety and quality.
